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Background: Polymorphisms within the PfATP6 gene have been indicated as potential molecular markers for
artemisinin efficacy. Since 2004, the use of artemisinin combination therapy (ACT) was introduced as first-line
treatment of the uncomplicated malaria cases in Suriname. The aim of this research was to determine changes in
Suriname in the status of the polymorphic markers in the PfATP6 gene before and after the adoption of the
ACT-regimen, particularly of the S769N mutation, which was reported to be associated with in vitro Artemether
resistance in the neighboring country French Guiana.
Methods: The PfATP6 gene from Plasmodium falciparum parasites in Suriname was investigated in 28 samples using
PCR amplification and restriction enzyme analysis, to assess and determine the prevalence of potentially interesting
single nucleotide polymorphisms. The polymorphisms [L263E; A623E; S769N], which may be associated with the
artemisinin resistant phenotype were characterized in parasites from three endemic regions before and after the
adoption of the ACT-regimen. In addition, the status of these molecular markers was compared in paired
P. falciparum isolates from patients with recurring malaria after controlled ACT.
Results: All the investigated samples exhibit the wild-type genotype at all three positions; L263, A623, S769.
Conclusion: All investigated isolates before and after the adoption of the ACT-regimen and independent of
endemic region harbored the wild-type genotype for the three investigated polymorphisms. The study revealed
that decreased artemisinin susceptibility could occur independent from PfATP6 mutations, challenging the
assumption that artemisinin resistance is associated with these mutations in the PfATP6 gene.Background
Artemisia annua extracts have been used for centuries
in traditional Chinese medicine, to treat febrile illnesses
including malaria. Currently, artemisinin, isolated from
the plant Artemisia annua and its synthetic derivatives
are worldwide the most potent and rapidly acting anti-
malarials. In 2003, the WHO recommended the use of
artemisinin-based combination therapy (ACT) [1].
Parasite resistance, especially of Plasmodium falcip-
arum, has been recorded to every utilized anti-malarial
drug [2], which calls for a diligent monitoring of emer-
ging artemisinin resistance in any malaria endemic area
especially in light of the large parasite populations in-
creasingly being exposed to artemisinins worldwide and
the actual development of artemisinin resistance in* Correspondence: m.adhin@uvs.edu
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reproduction in any medium, provided the orWestern Cambodia [3] and Thailand [4]. Various inde-
pendent experimental approaches corroborate the emer-
ging of artemisinin resistance: reports of cure rates
below 75% after artemether-lumefantrine treatment in
Cambodia [5]; the production of artemisinin-resistant
strains in vivo in the rodent malaria model Plasmodium
yoelii [6]; the selection of genetically stable and trans-
missible parasites resistant to artemisinin and artesunate
in P. chabaudi chabaudi [7] and the observation of
in vitro resistance to Artemether in isolates from French
Guiana [8] and in travelers returning from sub-Saharan
Africa [9].
These observations demonstrate that malaria parasites
are not only genetically and biologically capable of sus-
taining stable resistance to artemisinins, but also that
this resistance can be selected through drug pressure.
Resistance to the anti-malarial drugs pyrimethamine,
sulphadoxine and chloroquine is associated with specific
mutations in the pfdhfr, pfdhps and pfcrt gene,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on the notion of mutations responsible for the emerging
resistance to the class of artemisinin derived anti-
malarial drugs. Various individual molecules such as
haem, catalase, SERCA type enzymes have been pro-
posed as targets for artemisinins. Several observations
suggest that artemisinins inhibit the P. falciparum
sarco–endoplasmic reticulum Ca2+-ATPase (SERCA),
encoded by the gene denoted PfATP6 [10]. SERCA is a
key metabolic enzyme, which reduces the cytosolic free
calcium concentration.
Additional evidence that resistance to artemisinins
may depend on single mutations in the SERCA-type Ca2
+ ATPase was derived from a structure-function investi-
gation, identifying a potential hydrophobic interaction
between Leu263 of malarial SERCA’s with a side chain of
artemisinin derivatives [11] and several studies of
in vitro resistance to Artemether. In Senegal, one isolate
was a PfATPase6 E431K/A623E double mutant [8], in
sub Saharan Africa, isolates were linked to the A623E/
S769N haplotype [9] and in Suriname’s neighboring
country French Guiana alongside the border Maroni
river, an association with the S769N substitution was
revealed [8]. On the other hand, in vivo artemisinin re-
sistance could not be linked to mutations in the PfATP6
gene in clinical isolates from Cambodia [12].
The artemether-lumefantrine combination (CoartemW)
was introduced in Suriname as the first-line treatment of
malaria in January 2004 as part of an elaborate effort to
strengthen the national malaria programme.
An active trans-border migration, especially of gold
miners with high mobility and frequent use of counter-
feit drugs, exists between Suriname and neighboring
French Guiana, where in vitro resistance to Artemether
was observed [8]. Although no in vivo resistance to arte-
misinin derivatives or ACT had been reported from
French Guiana and artemisinin resistance was not yet
clinically documented in Suriname, the circumstances
called for an investigation of the potential emergence of
artemisinin resistance in accordance with the WHO
recommendations ‘to take urgent action to protect the
efficacy of ACT’ [13].
A retrospective molecular survey was conducted to as-
sess the status of three possible PfATP6 molecular mar-
kers for artemisinin resistance in clinical isolates
collected in the three leading endemic regions in
Suriname, including the border region with French
Guiana. Parasites from two different time periods in
Suriname were used to gain insight in the status of the
PfATP6 gene prior to and after the introduction of ACT
as first line anti-malarial drug. Furthermore, these poly-
morphisms of the PfATP6 gene were analyzed in paired
isolates from patients with recurring malaria after con-
trolled ACT therapy.Methods
Study site
Suriname is located along the North Coast of South
America, bordering French Guiana to the east, Guyana
to the west and Brazil to the south. Suriname has a
population of 492.829 people (50.3% male; 49.7% fe-
male), with 49.3% living in the coastal area in and
around the capital Paramaribo [14]. A savannah belt
separates the narrow coastal region from the tropical
rainforest of the interior, which covers 80% of the coun-
try. Malaria transmission is only observed in the interior
where 9.8% of the population lives in small Maroon or
Amerindian settlements.
Since the 1990s, small gold mining activities in the in-
terior attracted about 15,000 miners mostly from Brazil
and French Guiana, substantially increasing the people
at risk for malaria infection.
Anopheles darlingi is the predominant vector for mal-
aria transmission and P. falciparum, Plasmodium vivax
and Plasmodium malariae are the circulating species. In
2004, the country implemented a strengthened malaria
programme with several measures, such as introduction
of an ACT regimen, distribution of long-lasting impreg-
nated nets (LLINs), use of mobile units in the mining
areas and active case detection, which resulted in a spec-
tacular decrease of 14,403 malaria cases in 2003 to 1,371
cases in 2009 [15].
Study population
Within two independent anti-malarial drug efficacy
studies, Dried Blood Spots (DBS) were collected from
consenting positive patients from diverse age groups
with microscopically confirmed, uncomplicated P. falcip-
arum malaria. Random selections of these DBS were
used for this study, 10 samples collected in 2002 and 10
samples collected in 2005. Samples were from different
villages in three geographically diverse endemic regions
in Suriname (Marowijne, Boven Suriname and
Brokopondo).
Additionally, testing was performed on four paired fil-
ters (three from Marowijne, the border area with French
Guiana) from all patients in the latter study with recur-
ring malaria within 42 days after controlled use of ACT.
The observed ACT treatment failure rate was 4.6%
(n = 87) [16]. DBS from day 0 and day 42 were tested.
DNA isolation, amplification, restriction analysis and
recrudescence methods
DNA was isolated from DBS on filter paper using a
modified Saponin-Chelex extraction method [17].
Primary amplification of PfATP6 regions was followed
by nested PCR with mutation specific primers to identi-
fy potential polymorphisms for both the A623E and
L263E position.



















Original primer sequences from P. Cravo (personal communication).




PCR Temp. Time N. of
cycles
Primers
263 1st round PCR 92 °C 3 min 1 cycle 263P1 and
263P292 °C 30 sec 30 cycles
47 °C 45 sec
65 °C 1 min
68 °C 5 min 1 cycle
4 °C Hold 1 cycle
2nd round PCR 95 °C 3 min 1 cycle 263WT and
263 N1* 263 M
and 263 N1
95 °C 45 sec 20 cycles
62 °C 1 min
72 °C 1 min
72 °C 10 min 1 cycle
4 °C Hold 1 cycle
623-769 1st round PCR 94 °C 5 min 1 cycle ATP1 and
ATP294 °C 30 sec 45 cycles
44 °C 45 sec
68 °C 1 min
68 °C 5 min 1 cycle
4 °C Hold 1 cycle
623 2nd round PCR 94 °C 5 min 1 cycle 623WT and
623 N2* 623 M
and 623 N2
94 °C 30 sec 20 cycles
40 °C 45 sec
68 °C 1 min
70 °C 5 min 1 cycle
4 °C Hold 1 cycle
769 2nd round PCR 94 °C 5 min 1 cycle 769 N1 and
769 N294 °C 30 sec 25 cycles
56 °C 45 sec
68 °C 1 min
68 °C 5 min 1 cycle
4 °C Hold 1 cycle
(*) Second round PCR for codon 263 and 623 were performed in single
reactions with either the wild type (WT) or mutant (M) primer.
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fied with specifically designed primers containing an ar-
tificially introduced mismatch to generate a restriction
site (AflII) for the wild-type form of the two alternative
alleles for position 769. Substitutions at position S769N
were subsequently distinguished through enzyme diges-
tion with AflII. Primer sequences and PCR programs are
described in Tables 1 and 2.
Recrudescence analysis and repeat number poly-
morphisms assessment for the four paired filters con-
sisted of a first round PCR, followed by nested PCR for
the genes GLURP, MSP-1 and MSP-2 [18,19]. Sequence
polymorphisms in MSP-1 and MSP-2 were investigated
through restriction analysis with AluI, HinfI, DdeI, ScrfI
and RsaI.
For all PCRs, lack of cross-contamination was moni-
tored by the inclusion of negative control samples in
each PCR-run, while the consistency of the PCR-results
was confirmed through duplicate analysis of random
control samples. Amplified or digested DNA products
were separated through electrophoresis of polyacryl-
amide slab gels or horizontal agarose gels. Repeat num-
ber analysis or restriction patterns were analyzed on
either high-resolution agarose or polyacrylamide slab
gels in the presence of a molecular weight ladder. DNA
was detected with UV-illumination after staining with
ethidium bromide. Restriction efficacy in case of uncut
products was monitored by the inclusion of positive
control samples, which had to be completely digested, in
order to convincingly ascribe “uncut” restriction patterns
to the absence of the examined restriction site.
Results
Polymorphisms in the PfATP6 gene, encoding the SERCA-
type Plasmodium falciparum sarco–endoplasmic reticulumCa2+-ATPase, were assessed in 28 samples derived from
patients with microscopically confirmed uncomplicated
P. falciparummalaria, from three different endemic regions.
Sufficient DNA was recovered for all 28 samples and
single nucleotide polymorphic assays were successfully
performed for all three amino acid positions 263, 623
and 769.
The four paired samples of patients with recurring
malaria after controlled treatment were all indeed recru-
descent malaria isolates, as was demonstrated with re-
peat number and recrudescence analysis.
Position Leu263, was unaltered in all 28 investigated
samples and none of the isolates displayed the A623E
mutant genotype or the S769N mutation. It should be
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the border area with French Guiana still exhibited the
wild-type S769 haplotype.
Discussion
All 28 isolates exhibited an identical genotype for the
three investigated positions. No changes could be
detected either in samples obtained from geographical
different regions or in samples collected prior to or after
adopting an ACT regimen. However, all results should
be regarded as indications since the sample size was
small and an 18-24 months period is rather brief to exert
selection pressure. The absence of the S769N mutation
in clinical isolates corroborates the finding from neigh-
boring Brazil, suggesting that the mutant S769N haplo-
type has probably not yet spread regionally [20].
An important finding is the observed in vivo decreased
artemisinin susceptibility, as attested by recrudescent
malaria despite monitored treatment, independent of the
A623E, L263E and S769N mutations. Although the sam-
ple size was small, the results do not favor a direct asso-
ciation between these single nucleotide polymorphisms
and resistance to artemisinin, which is supported by re-
search on the P. chabaudi chabaudi ATP6 sequence re-
vealing no nucleotide changes following selection with
artesunate or artemisinin [7].
These results are also consistent with independent
investigations conducted in Tanzania [21] and other Af-
rican [22] and Asian [12] countries, where polymorph-
isms of PfATP6 could not be linked to artemisinin
resistance, but are in contrast with the findings in trave-
lers returning from sub-Saharan Africa [9], where the
A623E/S769N haplotype was linked to in vitro Arte-
mether resistance. Although several samples were col-
lected alongside the Maroni border river and even with
the recurring malaria isolates originating from this area,
the results from neighboring French Guiana where the
S769N mutation was reported to be associated with
in vitro Artemether resistance [8], could not be
substantiated.
The finding that generation of artemisinin resistant P.
chabaudi chabaudi clones failed in chloroquine sensitive
clones and was only successful in chloroquine resistant
clones [23] did not confound the results, since all inves-
tigated clones were resistant to chloroquine [Adhin, un-
published results].
In the light of accumulating evidence of artemisinin
resistance slowly emerging worldwide, diligent surveil-
lance is needed to monitor susceptibility to artemisinin
derivatives in endemic areas and these results under-
score the search for more appropriate molecular mar-
kers. The determination of pfmdr1 copy number and
single nucleotide polymorphisms in pfmdr1 alongside
PfATP6 analysis might be helpful, since conflictingreports exist about the association of increased pfmdr1
copy number and reduced susceptibility not only to
Mefloquine, but also to artemisinin [9,12,24]. The use of
other screening methods as monitoring parasitaemia
should be considered.
Conclusion
This report presents the first data for Suriname on single
nucleotide PfATP6 polymorphisms, potentially asso-
ciated with artemisinin resistance. Isolates obtained prior
to or after adopting CoartemW as first-line regimen do
not exhibit any mutations at the investigated poly-
morphisms since all the investigated samples from
Suriname harbor the wild-type genotype at all three
positions; L263E, A623E, S769N. The findings in French
Guiana regarding the S769N mutation could not be sub-
stantiated, despite the geographic vicinity. The occur-
rence of malaria relapses after controlled ACT without
altering the PfATP6 genotype at the investigated posi-
tions, proved the possibility of decrease of artemisinin
susceptibility independent of these mutations in the
PfATP6 gene.
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